Short Interest in UCB SA (OTCMKTS:UCBJF) Drops By 37.2%

UCB SA (OTCMKTS:UCBJF) was the recipient of a significant decline in short interest in the month of June. As of June 15th, there was short interest totaling 704,696 shares, a decline of 37.2% from the May 31st total of 1,121,617 shares. Approximately 0.4% of the shares of the company are short sold. Based on an average daily trading volume, of 831 shares, the days-to-cover ratio is currently 848.0 days.

UCB Stock Performance

Shares of OTCMKTS UCBJF opened at $305.24 on Thursday. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. UCB has a one year low of $194.76 and a one year high of $345.39. The business’s fifty day moving average price is $291.85 and its 200-day moving average price is $300.37.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.